Literature DB >> 14512172

Serum anti-Fas antibody levels in amyotrophic lateral sclerosis.

Ihsan S Sengun1, Stanley H Appel.   

Abstract

In this study, the levels of anti-Fas antibodies were evaluated in patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Sera from 25% of patients with sporadic ALS (sALS) and 22% of patients with familial ALS (fALS) contained abnormal levels of anti-Fas antibodies compared with normal controls. Half of patients with Parkinson's disease (PD), but no patients with Alzheimer's disease (AD), had abnormal levels of anti-Fas antibodies. There was no correlation between the antibody levels of patients with ALS and the length or stage of their disease. These data demonstrate that the peripheral immune system is activated as reflected by anti-Fas antibodies in ALS, but this activation is not specific to ALS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512172     DOI: 10.1016/s0165-5728(03)00263-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes.

Authors:  Shulamit Naor; Zohar Keren; Tomer Bronshtein; Efrat Goren; Marcelle Machluf; Doron Melamed
Journal:  J Neurol       Date:  2009-03-12       Impact factor: 4.849

2.  Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells.

Authors:  Meital Edri-Brami; Benyamin Rosental; Dana Hayoun; Michael Welt; Hila Rosen; Itzhak Wirguin; Beatrice Nefussy; Vivian E Drory; Angel Porgador; Rachel G Lichtenstein
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 3.  Death Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis.

Authors:  Julianne Aebischer; Nathalie Bernard-Marissal; Brigitte Pettmann; Cédric Raoul
Journal:  J Neurodegener Dis       Date:  2013-07-16

Review 4.  Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis.

Authors:  Melissa Bowerman; Thierry Vincent; Frédérique Scamps; Florence E Perrin; William Camu; Cédric Raoul
Journal:  Front Cell Neurosci       Date:  2013-11-19       Impact factor: 5.505

5.  Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.

Authors:  Rebecca Banerjee; R Lee Mosley; Ashley D Reynolds; Alok Dhar; Vernice Jackson-Lewis; Paul H Gordon; Serge Przedborski; Howard E Gendelman
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

Review 6.  Blood biomarkers for amyotrophic lateral sclerosis: myth or reality?

Authors:  Laura Robelin; Jose Luis Gonzalez De Aguilar
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.